travellinglight/iStock via Getty Images
Biogen (NASDAQ:BIIB)/Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY) on Wednesday announced data from long-term extension studies for their respective FDA-approved Alzheimer’s drugs, lecanemab-irmb (Leqembi) and donanemab-azbt (Kisunla).
Citing data from their open-label extension study of their Phase 3 Clarity AD trial, Biogen (NASDAQ:BIIB)/Eisai (OTCPK:ESAIY) said their anti-amyloid agent helped cut cognitive decline by 1.01 points over three years, according to the CDR-SB global cognitive and functional scale.
The result followed a comparison between the CDR-SB measure of Leqembi-treated patients and the cognitive decline expected in a group of patients taking part in a clinical research project called Alzheimer’s Disease Neuroimaging Initiative (ADNI).
There were no new safety signals after four years of Leqembi therapy, the companies added.
Meanwhile, based on early data from its TRAILBLAZER-ALZ 2 long-term extension trial, Eli Lilly (NYSE:LLY) said that, according to the CDR-SB, Kisunla cut cognitive decline by -0.6 points at 18 months and -1.2 points at 36 months versus the ADNI group. The long-term extension trial didn’t indicate any new safety signals over the three-year period, the Indiana-based pharma giant added.
Both readouts were shared at the ongoing 2025 Alzheimer’s Association International Conference in Toronto.